Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6223771 | 0.82 | PRMT5 (0.40) | ALDH1A1MAPTLMNAPKMCA12 | |
| SCHEMBL9654903 | 0.82 | PRMT5 (0.40) | ALDH1A1MAPTLMNAPKMCA12 | |
| SCHEMBL4898437 | 0.82 | PRMT5 (0.40) | ALDH1A1MAPTLMNAPKMCA12 | |
| SCHEMBL27535969 | 0.74 | CA12 (0.47) | ALDH1A1HSD17B10CA12MEN1KMT2A | |
| SCHEMBL7951069 | 0.71 | LMNA (0.43) | USP2ALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL27535977 | 0.70 | ALDH1A1 (0.46) | ALDH1A1HSD17B10CA12MEN1KMT2A | |
| SCHEMBL28857709 | 0.68 | ALDH1A1 (0.34) | ALDH1A1CA12MEN1KMT2A | |
| SCHEMBL11745005 | 0.68 | ALDH1A1 (0.51) | USP2ALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL7537706 | 0.68 | LMNA (0.47) | USP2ALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL7804489 | 0.67 | USP2 (0.44) | USP2ALDH1A1HPGDHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020115669-A1 | Oxazolidinone chemotherapeutic agents | ABBOTT LABORATORIES | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115669-A1 | Oxazolidinone chemotherapeutic agents | TOP1, OXA1L, TK1 | USP2 4543/4885ALDH1A1 105/4885HPGD 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.